This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study
International Journal of Hematology Open Access 09 September 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177–83.
Malpica L, Pimentel A, Reis IM, Gotuzzo E, Lekakis L, Komanduri K, et al. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2:607–20.
Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012;119:2141–8.
Inoue Y, Fuji S, Tanosaki R, Inamoto Y, Tanaka T, Ito A et al. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma. Bone Marrow Transplant 2018. E-pub ahead of print 2018/03/11; https://doi.org/10.1038/s41409-018-0139-z
Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42.
Michael M, Shimoni A, Nagler A. Regulatory T cells in allogeneic stem cell transplantation. Clin Dev Immunol. 2013;2013:608951.
Inoue Y, Fuji S, Tanosaki R, Fukuda T. Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transplant. 2016;51:725–7.
Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426–33.
Miyara M, Chader D, Sage E, Sugiyama D, Nishikawa H, Bouvry D, et al. Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3 high regulatory T cells in humans. Proc Natl Acad Sci USA. 2015;112:7225–30.
Fuji S, Shindo T. Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. Stem Cell Investig. 2016;3:70.
Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110:17945–50.
Sugata K, Yasunaga J-i, Miura M, Akari H, Utsunomiya A, Nosaka K, et al. Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody. Sci Rep. 2016;6:27150.
Itonaga H, Tsushima H, Taguchi J, Fukushima T, Taniguchi H, Sato S, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood. 2013;121:219–25.
Kobayashi S, Nakano K, Watanabe E, Ishigaki T, Ohno N, Yuji K, et al. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2014;20:2851–61.
Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899–911.
Acknowledgements
This research was partially supported by the Practical Research for Innovative Cancer Control Program of the Japan Agency for Medical Research and Development (15Ack0106136h0002).
Author contributions
YI, SE, NM, YK, TS, KK, AT, KI, NN, KN and MM participated in research design, data analysis, and writing of the paper. SF and TF participated in writing of the paper. All authors approved the submission of this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Inoue, Y., Endo, S., Matsuno, N. et al. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 54, 338–342 (2019). https://doi.org/10.1038/s41409-018-0291-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0291-5
This article is cited by
-
Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study
International Journal of Hematology (2023)
-
Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma
International Journal of Hematology (2023)
-
Prevention of acute graft-versus-host disease in adult T-cell leukemia–lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation
International Journal of Hematology (2022)
-
Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide
Bone Marrow Transplantation (2021)
-
Complement System: a Neglected Pathway in Immunotherapy
Clinical Reviews in Allergy & Immunology (2020)